GRTX — Galera Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Galera Therapeutics Inc - On Dec 6, Co Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq - Filing
Galera Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Galera Reports Third Quarter 2022 Financial Results
Galera Therapeutics Inc expected to post a loss of 52 cents a share - Earnings Preview
Brief: Galera Announces Presentation Of Phase 3 Roman Long-Term Follow-Up Data At 2022 American Society For Radiation Oncology (Astro) Annual Meeting
Galera Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Galera Therapeutics reports Q2 results
Brief: Galera Announces Results From Phase 1 Stage Of Greco-1 Trial Of Rucosopasem With SBRT For NSCLC
Brief: Galera Therapeutics - On June 8, Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Brief: Galera Announces Oral Presentation At 2022 American Society Of Clinical Oncology (Asco) Annual Meeting Detailing Results From Phase 3 Roman Trial Of Avasopasem
Galera Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Galera Therapeutics Reports Q1 Loss Per Share $0.58
Brief: Galera Announces Plan To Submit Avasopasem NDA By Year End
Galera Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview
Brief: Galera Announces Topline Results From Phase 2A Aesop Trial Of Avasopasem For Chemoradiotherapy-Induced Esophagitis
U.S. STOCKS ON THE MOVE-Halliburton, Couchbase, Newmont, Wingstop, Chevron
Galera Therapeutics rises as Q4 net loss narrows
Galera Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Galera Reports Fourth Quarter And Full Year 2021 Financial Results And Recent Corporate Updates